OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS

OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS

Show other versions (1)

<em>Early treatment with Pulmozyme (dornase alfa) and its prolonged use in combination with basis therapy results in decrease of exacerbation rate, prolongation of remission of bronchopulmonary process with normal ventilation functions of lungs and gives patients with cystic fibrosis an opport...

Full description

Bibliographic Details
Main Author:	O.I. Simonova
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2011-01-01
Series:	Вопросы современной педиатрии
Online Access:	http://vsp.spr-journal.ru:80/jour/article/view/659

Similar Items

OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
by: O.I. Simonova
Published: (2011-07-01)

DORNASE ALFA: WHAT EFFECTIVENESS OF MEDICATION DEPENDS ON?
by: O.I. Simonova
Published: (2009-01-01)

DORNASE ALFA: WHAT EFFECTIVENESS OF MEDICATION DEPENDS ON?
by: O.I. Simonova
Published: (2009-07-01)

DORNASE ALFA IN RUSSIA: 15 YEARS LATER. EFFICACY OF THE DRUG IN THE BASIC TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS
by: O. I. Simonova, et al.
Published: (2012-03-01)

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
by: Kyung Hwa Chang, et al.
Published: (2020-07-01)

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
by: Vito Terlizzi, et al.
Published: (2022-08-01)

Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
by: A.P. Earhart, et al.
Published: (2020-05-01)

Preliminary report of in vitro and in vivo effectiveness of dornase alfa on SARS-CoV-2 infection
by: H.K. Okur, et al.
Published: (2020-09-01)

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
by: Zachary M. Holliday, et al.
Published: (2021-10-01)

LONG TERM MUCOLYTIC THERAPY WITH DORNASE ALFA AT NOVOSIBIRSK CENTER FOR DIAGNOSTICS, TREATMENT, RHEABILITATION AND ADAPTATION OF CHILDREN WITH CYSTIC FIBROSIS
by: N.I. Romanenko, et al.
Published: (2006-03-01)

LONG TERM MUCOLYTIC THERAPY WITH DORNASE ALFA AT NOVOSIBIRSK CENTER FOR DIAGNOSTICS, TREATMENT, RHEABILITATION AND ADAPTATION OF CHILDREN WITH CYSTIC FIBROSIS
by: N.I. Romanenko, et al.
Published: (2006-01-01)

ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION)
by: E.B. Pavlinova, et al.
Published: (2007-03-01)

ESTIMATION OF THE MODERN MUCOLYTIC THERAPY EFFICACY IN CHILDREN, SUFFERING FROM MUCOVISCIDOSIS (TWO YEAR EXPERIENCE OF DORNASE ALFA APPLICATION)
by: E.B. Pavlinova, et al.
Published: (2007-01-01)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
by: Vito Terlizzi, et al.
Published: (2022-10-01)

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
by: Andrew G. Weber, et al.
Published: (2020-09-01)

A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
by: Tatiana Rozov, et al.
Published: (2013-12-01)

Dornase alpha use in patients with cystic fibrosis
by: Paulo José C. Marostica
Published: (2013-12-01)

Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study
by: Chuan Jiang, et al.
Published: (2020-08-01)

Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy
by: G. Crescimanno, et al.
Published: (2014-01-01)

Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
by: Michael H. Livingston, et al.
Published: (2017-06-01)

Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
by: Julien Pottecher, et al.
Published: (2020-03-01)

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
by: J. P. Desilles, et al.
Published: (2020-06-01)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
by: Ahmed Gibreel, et al.
Published: (2009-12-01)

ADMINISTRATION OF MUCOLYTICS WITH DIRECT ACTION IN PEDIATRIC PRACTICE
by: O. I. Simonova
Published: (2011-01-01)

ADMINISTRATION OF MUCOLYTICS WITH DIRECT ACTION IN PEDIATRIC PRACTICE
by: O. I. Simonova
Published: (2011-01-01)

Alfa Romeo /
by: 455329 Hull, Peter
Published: (1975)

THE VALUE OF THE COMPOUND DRUGS FORMOTEROL AND IPRATROPIUM BROMIDE IN COMPLEX TREATMENT OF CHRONIC NONSPECIFIC LUNG DISEASES IN CHILDREN
by: O.I. Simonova
Published: (2006-01-01)

NEW MEDICINAL FORM IN TREATMENT OF BRONCHIAL ASTHMA: FIXED COMBINATION OF FORMOTEROL AND BECLOMETASONE
by: O.I. Simonova
Published: (2010-01-01)

THE PLACE OF KINESITHERAPY IN BASIC TREATMENT OF CHRONIC NONSPECIFIC PULMONARY DISEASES IN CHILDREN: NEW METHODS, MISTAKES AND DIFFICULTIES
by: O.I. Simonova
Published: (2010-01-01)

AMBROXOL IN THE THERAPY OF THE RESPIRATORY PATHOLOGY AMONG CHILDREN
by: O.I. Simonova
Published: (2007-11-01)

THE PLACE OF KINESITHERAPY IN BASIC TREATMENT OF CHRONIC NONSPECIFIC PULMONARY DISEASES IN CHILDREN: NEW METHODS, MISTAKES AND DIFFICULTIES
by: O.I. Simonova
Published: (2010-07-01)

NEW MEDICINAL FORM IN TREATMENT OF BRONCHIAL ASTHMA: FIXED COMBINATION OF FORMOTEROL AND BECLOMETASONE
by: O.I. Simonova
Published: (2010-05-01)

THE VALUE OF THE COMPOUND DRUGS FORMOTEROL AND IPRATROPIUM BROMIDE IN COMPLEX TREATMENT OF CHRONIC NONSPECIFIC LUNG DISEASES IN CHILDREN
by: O.I. Simonova
Published: (2006-03-01)

AMBROXOL IN THE THERAPY OF THE RESPIRATORY PATHOLOGY AMONG CHILDREN
by: O.I. Simonova
Published: (2007-01-01)

INHALATION THERAPY: WHAT ITS ACTIVITY DEPENDS ON?
by: O.I. Simonova
Published: (2008-01-01)

INHALATION THERAPY: WHAT ITS ACTIVITY DEPENDS ON?
by: O.I. Simonova
Published: (2008-08-01)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
by: Alan Faraj, et al.
Published: (2023-07-01)

Fotoquímica de alfa,alfa-dimetilvalerofenona adsorvida em celulose microcristalina
by: Behrens Maria das Dores D., et al.
Published: (2006-01-01)

MUCOLYTIC AGENTS IN PEDIATRICS: RATIONAL SELECTION, THERAPEUTIC EFFECTS AND SPECIFIC ASPECTS OF TREATMENT
by: O. I. Simonova
Published: (2013-07-01)

The Alfa Romeo story
by: 239955 Wherry, Joseph H.
Published: (1967)